Divergent Findings on Interleukin Gum Disease Risk Test Raise Questions about Clinical Use | GenomeWeb

NEW YORK (GenomeWeb) – In the late 1990s, when genetics researcher Scott Diehl first came across data on Interleukin Genetics' test for assessing the risk of gum disease, he immediately noted weaknesses in the analyses.

"I was very troubled that the [genetic] test didn't have scientific validity," said Diehl, who from 1993 to 2002 was the chief of the molecular epidemiology and disease indicators branch at the National Institutes of Health's National Institute of Dental and Craniofacial Research.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.